Propranolol in treatment of hemangioma

Assessment of propranolol efficacy on pediatric hemangioma

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014041817325N1

Enrollment

Registered

2014-06-30

Start date

2012-08-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemangioma. Hemangioma, any site

Interventions

Propranolol 2 mg/kg twice a day for 6 month in case group. There is no control group..

Treatment - Drugs

Propranolol 2 mg/kg twice a day for 6 month in case group. There is no control group.

Eligibility

Sex/Gender

All

Age

1 Days to 14 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with hemangioma under 15 years old Exclusion criteria: Patients with cardiovascular disease; patients with history of low blood sugar; patients use another drugs last 6 months.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Regression of hemangioma (decrease in size). Timepoint: 1 week, 6month, 1 year. Method of measurement: Watchful, sonography if needed.	—

Secondary

Measure	Time frame
Decrease blood sugar. Timepoint: In first visit, after 1 week. Method of measurement: With glucometer.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNava Soleymani

Ardabil University of Medical Sciences

navasoleimani@gmail.com+98 45 1333 0633

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026